MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova announced the completion of the last patient last visit (LPLV) in its Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes. The randomized, double-blind, placebo-controlled trial enrolled patients receiving either 500 mg/day of MN-001 or placebo for 24 weeks. Top-line data are expected in Q3 2026.

05/26/2026, 7:00 PM • GlobeNewswire

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

A peer-reviewed study published in Cancer Research by Spanish National Cancer Research Centre (CNIO) identifies macrophage migration inhibitory factor (MIF)-mediated reprogramming as a central vulnerability in brain metastasis. The research demonstrates that MediciNova's lead compound MN-166 (ibudilast) can effectively block MIF-CD74 signaling and suppress brain metastasis growth in preclinical models. The study also identifies secreted MIF as a potential liquid biopsy biomarker in cerebrospinal fluid, supporting a biomarker-guided clinical strategy. MediciNova plans to collaborate with CNIO on future clinical research for patients with solid tumors having brain metastases.

04/27/2026, 7:00 PM • GlobeNewswire

MediciNova to Participate at the 38th Annual ROTH Conference

MediciNova announced that President and CEO Yuichi Iwaki and Chief Business Officer David H. Crean will participate in the 38th Annual ROTH Conference on March 22-24, 2026 in Dana Point, California. The executives will host one-on-one and small group meetings with investors to provide company updates on their clinical-stage biopharmaceutical pipeline.

03/16/2026, 7:00 AM • GlobeNewswire

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova announced that 100 patients have been enrolled in the SEANOBI expanded-access program evaluating MN-166 (ibudilast) for ALS treatment, representing 50% of the planned 200-patient enrollment across 12 US sites. The program is funded by a $22 million NIH/NINDS grant. MN-166 is also being evaluated in the COMBAT-ALS Phase 2b/3 trial with 234 patients enrolled, with top-line results expected by end of 2026.

01/29/2026, 6:00 PM • GlobeNewswire

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

MediciNova completed randomization of 234 patients in its COMBAT-ALS clinical trial for MN-166, a potential treatment for Amyotrophic Lateral Sclerosis. The company anticipates top-line data by end of 2026 and remains hopeful about the drug's therapeutic potential.

12/08/2025, 6:00 AM • GlobeNewswire

Message from the CEO to MediciNova Shareholders

MediciNova published research demonstrating how its drug MN-001 potentially improves cholesterol transport and addresses metabolic disorders, with Phase 2 trial results expected in summer 2026.

12/01/2025, 6:00 PM • GlobeNewswire

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

MediciNova received the Contract Research and Development Innovation Award for its innovative work on MN-166, a small molecule drug candidate targeting neurological diseases like ALS, demonstrating promising therapeutic potential.

11/06/2025, 6:00 PM • GlobeNewswire

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

MediciNova completed enrollment for its COMBAT-ALS Phase 2b/3 clinical trial of MN-166, a potential treatment for Amyotrophic Lateral Sclerosis (ALS), marking a significant milestone in neurodegenerative disease research.

08/26/2025, 7:00 PM • GlobeNewswire

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

MediciNova secured a $30 million standby equity purchase agreement with Yorkville Advisors, allowing flexible capital raising over 36 months to support ongoing R&D programs without issuing warrants.

07/31/2025, 7:30 PM • GlobeNewswire